Anti-cytokine therapy, such as anti-TNF and IL-6 therapy, is used in the treatment of IBD, which improves the therapeutic efficiency and prevents the occurrence of CAC (Table 1) [282–284]. This evidence concerns the gene IL6 and irritable bowel syndrome.